MARC보기
LDR02125nam u200421 4500
001000000420533
00520190215164543
008181129s2018 |||||||||||||||||c||eng d
020 ▼a 9780438132801
035 ▼a (MiAaPQ)AAI10752166
035 ▼a (MiAaPQ)medicine.yale:10714
040 ▼a MiAaPQ ▼c MiAaPQ ▼d 247004
0820 ▼a 610
1001 ▼a Ader, Jeremy.
24510 ▼a Precision Medicine in Atrial Fibrillation: A Risk Model for Management with Dabigatran v. Warfarin.
260 ▼a [S.l.]: ▼b Yale University., ▼c 2018.
260 1 ▼a Ann Arbor: ▼b ProQuest Dissertations & Theses, ▼c 2018.
300 ▼a 75 p.
500 ▼a Source: Dissertation Abstracts International, Volume: 79-11(E), Section: B.
500 ▼a Adviser: Nihar R. Desai.
5021 ▼a Thesis (M.D.)--Yale University, 2018.
520 ▼a The Precision Medicine Initiative aims to advance Medicine from "one-size-fits-all" treatments to more individualized approaches. Clinical trials evaluate treatments by analyzing average outcomes, and thus risk overlooking potential differences
520 ▼a We analyzed the Randomized Evaluation of Long-Term Anticoagulation Therapy (RELY) trial of dabigatran versus warfarin in patients with atrial fibrillation, to determine if the application of multivariate predictive models could demonstrate heter
520 ▼a These findings demonstrate heterogeneity of treatment effect in the RE-LY trial, and the ability of multivariate risk models to identify distinct treatment risks for individual patients. Such models could be used in clinical practice provide pat
590 ▼a School code: 0265.
650 4 ▼a Medicine.
650 4 ▼a Epidemiology.
690 ▼a 0564
690 ▼a 0766
71020 ▼a Yale University. ▼b Yale School of Medicine.
7730 ▼t Dissertation Abstracts International ▼g 79-11B(E).
773 ▼t Dissertation Abstract International
790 ▼a 0265
791 ▼a M.D.
792 ▼a 2018
793 ▼a English
85640 ▼u http://www.riss.kr/pdu/ddodLink.do?id=T14997216 ▼n KERIS ▼z 이 자료의 원문은 한국교육학술정보원에서 제공합니다.
980 ▼a 201812 ▼f 2019
990 ▼a ***1012033